Study finds Alzheimer’s drugs might boost healthy protein in brain
Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought … Click to Continue »
View original article
Contributor:
